EGFR and non-small cell lung carcinoma: Several studies have proven that PD-L1 expression is correlated with wild-type EGFR [12, 14, 15], ROS1 rearrangement [14], and erlotinib-resistant NSCLC [6], while it is not associated with ALK mutations [16].